Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hemab Therapeutics HoldingsCOAG 12 PB Ratio is 4.24 as of Sep. 20, 2026. GuruFocus rates COAG with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 1,223 Biotechnology companies, Hemab Therapeutics Holdings ranks worse than 64.84% on this metric.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Hemab Therapeutics Holdings PB Ratio Related Terms
Hemab Therapeutics Holdings PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hemab Therapeutics Holdings PB Ratio Chart
Hemab Therapeutics Holdings Annual Data
Trend
Dec24
Dec25
PB Ratio
-
-
Hemab Therapeutics Holdings Quarterly Data
Mar25
Jun25
Mar26
Jun26
PB Ratio
-
-
-
3.78
COAG vs ADMA, VCEL, KLRA: PB Ratio Comparison
For the Biotechnology subindustry, Hemab Therapeutics Holdings's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hemab Therapeutics Holdings PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hemab Therapeutics Holdings's PB Ratio distribution charts can be found below:
* The bar in red indicates where Hemab Therapeutics Holdings's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Hemab Therapeutics Holdings (COAG) has a PB Ratio of 4.24 as of Sep. 20, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Hemab Therapeutics Holdings and its competitors. According to the industry distribution chart, Hemab Therapeutics Holdings ranks #793 out of 1223 companies in the Biotechnology industry, placing it in the top 64.8%.
Is Hemab Therapeutics Holdings' PB Ratio too high?
Hemab Therapeutics Holdings' current PB Ratio is 4.24. The Biotechnology industry median PB Ratio is 2.92. Hemab Therapeutics Holdings' value of 4.24 is 45.2% above this industry median. Based on the distribution chart, Hemab Therapeutics Holdings ranks #793 out of 1223 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Hemab Therapeutics Holdings has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Hemab Therapeutics Holdings' PB Ratio compare to ADMA and VCEL?
According to the Biotechnology industry distribution chart, Hemab Therapeutics Holdings ranks #793 out of 1223 companies for PB Ratio. This places Hemab Therapeutics Holdings in the lower half of its industry. The industry median PB Ratio is 2.92. Hemab Therapeutics Holdings' value of 4.24 is 45.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.92, based on 1,223 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hemab Therapeutics Holdings's current PB Ratio of 4.24 is 45.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Hemab Therapeutics Holdings and its competitors. For the Biotechnology industry, the median PB Ratio is 2.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hemab Therapeutics Holdings's current PB Ratio is 4.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hemab Therapeutics Holdings stock overvalued right now?
Hemab Therapeutics Holdings (COAG) has a current PB Ratio of 4.24. The current PB Ratio is 4.24 and 45.2% above the Biotechnology industry median of 2.92. Hemab Therapeutics Holdings' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Hemab Therapeutics Holdings (COAG), the current PB Ratio is 4.24 as of Sep. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.
12GF Score
Get the complete analysis for COAG
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COAG has been successfully added to your 
